Cittadine Andrew has filed 59 insider transactions across 1 company since December 2022.
Most recent transaction: a option exercise of 3514 shares of Monopar Therapeutics ($MNPR) on March 31, 2026.
Activity breakdown: 10 open-market purchases and 0 sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 31, 2026 | Monopar Therapeutics | $MNPR | Cittadine Andrew | Chief Operating Officer | M | Restricted Stock Unit | 3514 | $0.00 | 44,753.0000 | 6,662,930 | 7.28% | 0.05% |
| March 31, 2026 | Monopar Therapeutics | $MNPR | Cittadine Andrew | Chief Operating Officer | F | Common Stock | 1571 | $54.79 | 52,669.0000 | 6,662,930 | 2.90% | 0.02% |
| March 31, 2026 | Monopar Therapeutics | $MNPR | Cittadine Andrew | Chief Operating Officer | M | Common Stock | 3514 | $0.00 | 54,240.0000 | 6,662,930 | 6.93% | 0.05% |
| Dec. 31, 2025 | Monopar Therapeutics | $MNPR | Cittadine Andrew | Chief Operating Officer | M | Common Stock | 4326 | $0.00 | 52,615.0000 | 6,662,930 | 8.96% | 0.06% |
| Dec. 31, 2025 | Monopar Therapeutics | $MNPR | Cittadine Andrew | Chief Operating Officer | F | Common Stock | 1889 | $65.30 | 50,726.0000 | 6,662,930 | 3.59% | 0.03% |
| Dec. 31, 2025 | Monopar Therapeutics | $MNPR | Cittadine Andrew | Chief Operating Officer | M | Restricted Stock Unit | 4326 | $0.00 | 48,267.0000 | 6,662,930 | 8.23% | 0.06% |
| Dec. 2, 2025 | Monopar Therapeutics | $MNPR | Cittadine Andrew | Chief Operating Officer | A | Restricted Stock Units | 13919 | $0.00 | 52,593.0000 | 6,662,930 | 35.99% | 0.21% |
| Dec. 2, 2025 | Monopar Therapeutics | $MNPR | Cittadine Andrew | Chief Operating Officer | A | Stock Options | 8969 | $0.00 | 8,969.0000 | 6,662,930 | 9999.99% | 0.13% |
| Sept. 30, 2025 | Monopar Therapeutics | $MNPR | Cittadine Andrew | Chief Operating Officer | M | Restricted Stock Units | 4327 | $0.00 | 38,674.0000 | 6,102,560 | 10.06% | 0.07% |
| Sept. 30, 2025 | Monopar Therapeutics | $MNPR | Cittadine Andrew | Chief Operating Officer | M | Common Stock | 4327 | $0.00 | 50,185.0000 | 6,102,560 | 9.44% | 0.07% |
| Sept. 30, 2025 | Monopar Therapeutics | $MNPR | Cittadine Andrew | Chief Operating Officer | F | Common Stock | 1896 | $81.67 | 48,289.0000 | 6,102,560 | 3.78% | 0.03% |
| June 30, 2025 | Monopar Therapeutics | $MNPR | Cittadine Andrew | Chief Operating Officer | F | Common Stock | 2990 | $35.78 | 45,858.0000 | 6,102,560 | 6.12% | 0.05% |
| June 30, 2025 | Monopar Therapeutics | $MNPR | Cittadine Andrew | Chief Operating Officer | M | Restricted Stock Units | 6863 | $0.00 | 43,001.0000 | 6,102,560 | 13.76% | 0.11% |
| June 30, 2025 | Monopar Therapeutics | $MNPR | Cittadine Andrew | Chief Operating Officer | M | Common Stock | 6863 | $0.00 | 48,848.0000 | 6,102,560 | 16.35% | 0.11% |
| March 31, 2024 | Monopar Therapeutics | $MNPR | Cittadine Andrew | Chief Operating Officer | M | Restricted Stock Units | 1791 | $0.00 | 49,864.0000 | 2,980,900 | 3.47% | 0.06% |
| March 31, 2025 | Monopar Therapeutics | $MNPR | Cittadine Andrew | Chief Operating Officer | F | Common Stock | 744 | $36.41 | 41,985.0000 | 6,102,560 | 1.74% | 0.01% |
| March 31, 2025 | Monopar Therapeutics | $MNPR | Cittadine Andrew | Chief Operating Officer | M | Common Stock | 1791 | $0.00 | 42,729.0000 | 6,102,560 | 4.37% | 0.03% |
| March 4, 2025 | Monopar Therapeutics | $MNPR | Cittadine Andrew | Chief Operating Officer | A | Restricted Stock Units | 40581 | $0.00 | 51,655.0000 | 6,102,560 | 366.45% | 0.66% |
| March 4, 2025 | Monopar Therapeutics | $MNPR | Cittadine Andrew | Chief Operating Officer | A | Stock Options | 43445 | $0.00 | 43,445.0000 | 6,102,560 | 9999.99% | 0.71% |
| Dec. 31, 2024 | Monopar Therapeutics | $MNPR | Cittadine Andrew | Chief Operating Officer | M | Common Stock | 1790 | $0.00 | 41,659.0000 | 3,520,427 | 4.49% | 0.05% |
| Dec. 31, 2024 | Monopar Therapeutics | $MNPR | Cittadine Andrew | Chief Operating Officer | F | Common Stock | 721 | $22.00 | 40,938.0000 | 3,520,427 | 1.73% | 0.02% |
| Dec. 31, 2024 | Monopar Therapeutics | $MNPR | Cittadine Andrew | Chief Operating Officer | M | Restricted Stock Units | 1790 | $0.00 | 11,074.0000 | 3,520,427 | 13.91% | 0.05% |
| Sept. 30, 2024 | Monopar Therapeutics | $MNPR | Cittadine Andrew | Chief Operating Officer | M | Common Stock | 1791 | $0.00 | 40,404.0000 | 3,520,427 | 4.64% | 0.05% |
| Sept. 30, 2024 | Monopar Therapeutics | $MNPR | Cittadine Andrew | Chief Operating Officer | M | Restricted Stock Units | 1791 | $0.00 | 12,864.0000 | 3,520,427 | 12.22% | 0.05% |
| Sept. 30, 2024 | Monopar Therapeutics | $MNPR | Cittadine Andrew | Chief Operating Officer | F | Common Stock | 535 | $6.74 | 39,869.0000 | 3,520,427 | 1.32% | 0.02% |
| June 30, 2024 | Monopar Therapeutics | $MNPR | Cittadine Andrew | Chief Operating Officer | F | Common Stock | 2019 | $0.73 | 193,065.0000 | 2,980,900 | 1.03% | 0.07% |
| June 30, 2024 | Monopar Therapeutics | $MNPR | Cittadine Andrew | Chief Operating Officer | M | Common Stock | 8952 | $0.00 | 195,084.0000 | 2,980,900 | 4.81% | 0.30% |
| June 30, 2024 | Monopar Therapeutics | $MNPR | Cittadine Andrew | Chief Operating Officer | M | Restricted Stock Units | 8952 | $0.00 | 73,271.0000 | 2,980,900 | 10.89% | 0.30% |
| June 20, 2024 | Monopar Therapeutics | $MNPR | Cittadine Andrew | Chief Operating Officer | P | Common Stock | 20508 | $0.74 | 186,132.0000 | 2,980,900 | 12.38% | 0.69% |
| June 18, 2024 | Monopar Therapeutics | $MNPR | Cittadine Andrew | Chief Operating Officer | P | Common Stock | 12000 | $0.86 | 165,624.0000 | 2,980,900 | 7.81% | 0.40% |
| June 13, 2024 | Monopar Therapeutics | $MNPR | Cittadine Andrew | Chief Operating Officer | P | Common Stock | 12000 | $0.91 | 129,624.0000 | 2,980,900 | 10.20% | 0.40% |
| June 14, 2024 | Monopar Therapeutics | $MNPR | Cittadine Andrew | Chief Operating Officer | P | Common Stock | 12000 | $0.93 | 141,624.0000 | 2,980,900 | 9.26% | 0.40% |
| June 17, 2024 | Monopar Therapeutics | $MNPR | Cittadine Andrew | Chief Operating Officer | P | Common Stock | 12000 | $0.90 | 153,624.0000 | 2,980,900 | 8.47% | 0.40% |
| June 3, 2024 | Monopar Therapeutics | $MNPR | Cittadine Andrew | Chief Operating Officer | P | Common Stock | 12000 | $0.76 | 105,624.0000 | 2,980,900 | 12.82% | 0.40% |
| June 4, 2024 | Monopar Therapeutics | $MNPR | Cittadine Andrew | Chief Operating Officer | P | Common Stock | 12000 | $0.78 | 117,624.0000 | 2,980,900 | 11.36% | 0.40% |
| May 31, 2024 | Monopar Therapeutics | $MNPR | Cittadine Andrew | Chief Operating Officer | P | Common Stock | 12000 | $0.64 | 93,624.0000 | 2,980,900 | 14.70% | 0.40% |
| May 29, 2024 | Monopar Therapeutics | $MNPR | Cittadine Andrew | Chief Operating Officer | P | Common Stock | 12000 | $0.64 | 69,624.0000 | 2,980,900 | 20.82% | 0.40% |
| May 30, 2024 | Monopar Therapeutics | $MNPR | Cittadine Andrew | Chief Operating Officer | P | Common Stock | 12000 | $0.64 | 81,624.0000 | 2,980,900 | 17.24% | 0.40% |
| May 22, 2024 | Monopar Therapeutics | $MNPR | Cittadine Andrew | Chief Operating Officer | A | Stock Options | 25000 | $0.00 | 25,000.0000 | 2,980,900 | 9999.99% | 0.84% |
| March 31, 2024 | Monopar Therapeutics | $MNPR | Cittadine Andrew | Chief Operating Officer | M | Common Stock | 8952 | $0.00 | 60,722.0000 | 2,980,900 | 17.29% | 0.30% |
| March 31, 2024 | Monopar Therapeutics | $MNPR | Cittadine Andrew | Chief Operating Officer | M | Restricted Stock Units | 8952 | $0.00 | 82,223.0000 | 2,980,900 | 9.82% | 0.30% |
| March 31, 2024 | Monopar Therapeutics | $MNPR | Cittadine Andrew | Chief Operating Officer | F | Common Stock | 3098 | $0.68 | 57,624.0000 | 2,980,900 | 5.10% | 0.10% |
| Dec. 31, 2023 | Monopar Therapeutics | $MNPR | Cittadine Andrew | Chief Operating Officer | M | Restricted Stock Units | 8952 | $0.00 | 91,175.0000 | 0 | 8.94% | 0.00% |
| Dec. 31, 2023 | Monopar Therapeutics | $MNPR | Cittadine Andrew | Chief Operating Officer | F | Common Stock | 3098 | $0.34 | 51,770.0000 | 0 | 5.65% | 0.00% |
| Dec. 31, 2023 | Monopar Therapeutics | $MNPR | Cittadine Andrew | Chief Operating Officer | M | Common Stock | 8952 | $0.00 | 54,868.0000 | 0 | 19.50% | 0.00% |
| Sept. 30, 2023 | Monopar Therapeutics | $MNPR | Cittadine Andrew | Chief Operating Officer | M | Common Stock | 8953 | $0.00 | 48,540.0000 | 0 | 22.62% | 0.00% |
| Sept. 30, 2023 | Monopar Therapeutics | $MNPR | Cittadine Andrew | Chief Operating Officer | F | Common Stock | 2624 | $0.62 | 45,916.0000 | 0 | 5.41% | 0.00% |
| Sept. 30, 2023 | Monopar Therapeutics | $MNPR | Cittadine Andrew | Chief Operating Officer | M | Restricted Stock Units | 8953 | $0.00 | 100,127.0000 | 0 | 8.21% | 0.00% |
| June 30, 2023 | Monopar Therapeutics | $MNPR | Cittadine Andrew | Chief Operating Officer | M | Restricted Stock Units | 13841 | $0.00 | 109,080.0000 | 0 | 11.26% | 0.00% |
| June 30, 2023 | Monopar Therapeutics | $MNPR | Cittadine Andrew | Chief Operating Officer | M | Common Stock | 13841 | $0.00 | 43,644.0000 | 0 | 46.44% | 0.00% |
| June 30, 2023 | Monopar Therapeutics | $MNPR | Cittadine Andrew | Chief Operating Officer | F | Common Stock | 4057 | $0.86 | 39,587.0000 | 0 | 9.30% | 0.00% |
| March 31, 2023 | Monopar Therapeutics | $MNPR | Cittadine Andrew | Chief Operating Officer | M | Common Stock | 4063 | $0.00 | 30,957.0000 | 0 | 15.11% | 0.00% |
| March 31, 2023 | Monopar Therapeutics | $MNPR | Cittadine Andrew | Chief Operating Officer | F | Common Stock | 1154 | $1.39 | 29,803.0000 | 0 | 3.73% | 0.00% |
| March 31, 2023 | Monopar Therapeutics | $MNPR | Cittadine Andrew | Chief Operating Officer | M | Restricted Stock Units | 4063 | $0.00 | 44,687.0000 | 0 | 8.33% | 0.00% |
| Feb. 1, 2023 | Monopar Therapeutics | $MNPR | Cittadine Andrew | Chief Operating Officer | A | Restricted Stock Units | 78234 | $0.00 | 126,984.0000 | 0 | 160.48% | 0.00% |
| Feb. 1, 2023 | Monopar Therapeutics | $MNPR | Cittadine Andrew | Chief Operating Officer | A | Stock Options | 102688 | $0.00 | 102,688.0000 | 0 | 9999.99% | 0.00% |
| Dec. 31, 2022 | Monopar Therapeutics | $MNPR | Cittadine Andrew | Chief Operating Officer | M | Restricted Stock Units | 4062 | $0.00 | 48,750.0000 | 0 | 7.69% | 0.00% |
| Dec. 31, 2022 | Monopar Therapeutics | $MNPR | Cittadine Andrew | Chief Operating Officer | F | Common Stock | 1406 | $2.37 | 26,894.0000 | 0 | 4.97% | 0.00% |
| Dec. 31, 2022 | Monopar Therapeutics | $MNPR | Cittadine Andrew | Chief Operating Officer | M | Common Stock | 4062 | $0.00 | 28,300.0000 | 0 | 16.76% | 0.00% |